Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1991 1
1997 1
1999 4
2000 32
2001 18
2002 14
2003 20
2004 15
2005 19
2006 23
2007 28
2008 45
2009 46
2010 49
2011 49
2012 85
2013 96
2014 126
2015 125
2016 156
2017 153
2018 174
2019 178
2020 233
2021 248
2022 243
2023 243
2024 67

Text availability

Article attribute

Article type

Publication date

Search Results

2,187 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis.
Finnerty JP, Ponnuswamy A, Dutta P, Abdelaziz A, Kamil H. Finnerty JP, et al. BMC Pulm Med. 2021 Dec 11;21(1):411. doi: 10.1186/s12890-021-01783-1. BMC Pulm Med. 2021. PMID: 34895203 Free PMC article.
BACKGROUND: Research questions To compare the efficacy of nintedanib and pirfenidone in the treatment of progressive pulmonary fibrosis; and to compare the efficacy of anti-fibrotic therapy (grouping nintedanib and pirfenidone together) in patients with IPF versus patients …
BACKGROUND: Research questions To compare the efficacy of nintedanib and pirfenidone in the treatment of progressive pulmonary fibrosis …
Improving nutrition in cystic fibrosis: A systematic literature review.
Mielus M, Sands D, Woynarowski M. Mielus M, et al. Nutrition. 2022 Oct;102:111725. doi: 10.1016/j.nut.2022.111725. Epub 2022 May 6. Nutrition. 2022. PMID: 35816813 Free article. Review.
With increasing life expectancy of patients with cystic fibrosis (CF), gastrointestinal manifestations of the disease have been increasingly brought into focus. ...
With increasing life expectancy of patients with cystic fibrosis (CF), gastrointestinal manifestations of the disease have been incre …
Physical exercise training for cystic fibrosis.
Radtke T, Nevitt SJ, Hebestreit H, Kriemler S. Radtke T, et al. Cochrane Database Syst Rev. 2017 Nov 1;11(11):CD002768. doi: 10.1002/14651858.CD002768.pub4. Cochrane Database Syst Rev. 2017. PMID: 29090734 Free PMC article. Updated. Review.
AUTHORS' CONCLUSIONS: Evidence about the efficacy of physical exercise training in cystic fibrosis from 15 small studies with low to moderate methodological quality is limited. ...High-quality randomised controlled trials are needed to comprehensively assess the benefits o …
AUTHORS' CONCLUSIONS: Evidence about the efficacy of physical exercise training in cystic fibrosis from 15 small studies with low to …
Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review.
Hutchinson J, Fogarty A, Hubbard R, McKeever T. Hutchinson J, et al. Eur Respir J. 2015 Sep;46(3):795-806. doi: 10.1183/09031936.00185114. Epub 2015 May 14. Eur Respir J. 2015. PMID: 25976683 Free article. Review.
As idiopathic pulmonary fibrosis emerges as an important public health problem, there is a need to coordinate data on incidence and mortality globally. ...The majority of studies showed an increase in incidence over time.The incidence of idiopathic pulmonary fibrosis …
As idiopathic pulmonary fibrosis emerges as an important public health problem, there is a need to coordinate data on incidence and m …
Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis.
Dulai PS, Singh S, Patel J, Soni M, Prokop LJ, Younossi Z, Sebastiani G, Ekstedt M, Hagstrom H, Nasr P, Stal P, Wong VW, Kechagias S, Hultcrantz R, Loomba R. Dulai PS, et al. Hepatology. 2017 May;65(5):1557-1565. doi: 10.1002/hep.29085. Epub 2017 Mar 31. Hepatology. 2017. PMID: 28130788 Free PMC article. Review.
Quantitative risk of mortality by fibrosis stage has not been systematically evaluated. We aimed to quantify the fibrosis stage-specific risk of all-cause and liver-related mortality in NAFLD. Through a systematic review and meta-analysis, we identified five adult N …
Quantitative risk of mortality by fibrosis stage has not been systematically evaluated. We aimed to quantify the fibrosis stag …
Nintedanib in Progressive Pulmonary Fibrosis: A Systematic Review and Meta-Analysis.
Ghazipura M, Mammen MJ, Herman DD, Hon SM, Bissell BD, Macrea M, Kheir F, Khor YH, Knight SL, Raghu G, Wilson KC, Hossain T. Ghazipura M, et al. Ann Am Thorac Soc. 2022 Jun;19(6):1040-1049. doi: 10.1513/AnnalsATS.202103-343OC. Ann Am Thorac Soc. 2022. PMID: 35499854
Objective: To conduct a systematic review to evaluate existing ILD literature to determine whether patients with progressive pulmonary fibrosis (PPF) should be treated with the antifibrotic nintedanib. ...Conclusions: Nintedanib use in patients with PPF is associated with …
Objective: To conduct a systematic review to evaluate existing ILD literature to determine whether patients with progressive pulmonary fi …
Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies.
Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Singh S, et al. Clin Gastroenterol Hepatol. 2015 Apr;13(4):643-54.e1-9; quiz e39-40. doi: 10.1016/j.cgh.2014.04.014. Epub 2014 Apr 24. Clin Gastroenterol Hepatol. 2015. PMID: 24768810 Free PMC article. Review.
Over 2145.5 person-years of follow-up evaluation, 33.6% had fibrosis progression, 43.1% had stable fibrosis, and 22.3% had an improvement in fibrosis stage. The annual fibrosis progression rate in patients with NAFL who had stage 0 fibrosis at b …
Over 2145.5 person-years of follow-up evaluation, 33.6% had fibrosis progression, 43.1% had stable fibrosis, and 22.3% had an …
Efficacy of Pirfenidone and Nintedanib in Interstitial Lung Diseases Other than Idiopathic Pulmonary Fibrosis: A Systematic Review.
Amati F, Stainer A, Polelli V, Mantero M, Gramegna A, Blasi F, Aliberti S. Amati F, et al. Int J Mol Sci. 2023 Apr 25;24(9):7849. doi: 10.3390/ijms24097849. Int J Mol Sci. 2023. PMID: 37175556 Free PMC article. Review.
Pirfenidone and nintedanib are antifibrotic medications approved for idiopathic pulmonary fibrosis treatment by regulatory agencies and available for clinical use worldwide. These drugs have been shown to reduce the rate of decline in forced vital capacity and the risk of …
Pirfenidone and nintedanib are antifibrotic medications approved for idiopathic pulmonary fibrosis treatment by regulatory agencies a …
Medical treatments for idiopathic pulmonary fibrosis: a systematic review and network meta-analysis.
Pitre T, Mah J, Helmeczi W, Khalid MF, Cui S, Zhang M, Husnudinov R, Su J, Banfield L, Guy B, Coyne J, Scallan C, Kolb MR, Jones A, Zeraatkar D. Pitre T, et al. Thorax. 2022 Dec;77(12):1243-1250. doi: 10.1136/thoraxjnl-2021-217976. Epub 2022 Feb 10. Thorax. 2022. PMID: 35145039
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a respiratory disorder with a poor prognosis. Our objective is to assess the comparative effectiveness of 22 approved or studied IPF drug treatments. ...
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a respiratory disorder with a poor prognosis. Our objective is to assess the compa …
Impact of Antifibrotic Therapy on Mortality and Acute Exacerbation in Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis.
Petnak T, Lertjitbanjong P, Thongprayoon C, Moua T. Petnak T, et al. Chest. 2021 Nov;160(5):1751-1763. doi: 10.1016/j.chest.2021.06.049. Epub 2021 Jul 2. Chest. 2021. PMID: 34217681
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a progressive fibrosing interstitial lung disease associated with significant morbidity and mortality. ...
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a progressive fibrosing interstitial lung disease associated with significant morb …
2,187 results